Advertisement

Topics

Companies Related to "A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI" [Most Relevant Company Matches] RSS

03:43 EDT 19th August 2018 | BioPortfolio

Here are the most relevant search results for "A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI" found in our extensive corporate database of over 50,000 company records.

Showing "Randomized Placebo Controlled Trial Examine Efficacy Oral Donepezil" Companies 1–25 of 1,700+

Extremely Relevant

Adeona Pharmaceuticals, Inc.

Adeona (AMEX: AEN) is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona's primary strategy is to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to an inflection point in valuation resulting in a significant development and marketing collaboration. Trimesta (estriol) ...


Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully...

DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a comm...


Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec(®) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute ...

Agennix

Agennix is a privately held biotechnology company whose lead molecule, Talactoferrin Alfa (talactoferrin; TLF), is an immunomodulatory protein. Agennix is currently preparing to initiate Phase III development of oral talactoferrin for cancer, and topical talactoferrin gel for wound healing.Liquid talactoferrin is an oral anti-cancer drug that has shown activity both as monotherapy and in combinati...

Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is focusing on development ...

Cypress Bioscience

We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications....

Relevant

Polynoma, Inc.

Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL 103A for the treatment of melanoma. The Phase 3 trial of POL 103A was initiated based on two randomized, controlled Phase 2 trials that showed statistically significant efficacy ...

Favrille

We are a biopharmaceutical company focused on the development and commercialization of patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system. We own a proprietary technology that enables us to efficiently develop and manufacture active immunotherapy products designed to stimulate a patient's own immune system to mount a specific and sustained response...

Privia

A clinical trial is a research study. Research studies are used to decide how treatments work and how safe they are. While in a study, a person may receive either an investigational drug, a marketed drug, a placebo, or a combination of these. An investigational drug is one that is nor approved by the Food and Drug Administration, a marketed drug is FDA approved and a placebo is like a "sugar pill"...

Synovics Pharmaceuticals

Synovics is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of oral controlled-release generic drugs and improved formulations of previously approved drugs. The Company has licensed exclusive and worldwide rights to employ certain proprietary oral controlled-release drug formulation technologies. Synovics is undertaking the initiation of US develo...

Opsona Therapeutics Ltd

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Opsona Therapeutics Limited

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in t...

Amarillo Biosciences Incorporated

Amarillo Biosciences, Inc., (ABI), is a biopharmaceutical company developing low-dose oral and topical interferon alpha. We are directing our research at the treatment of Behcet's Disease, and oral warts in HIV+ patients and chronic cough in idiopathic pulmonary fibrosis. Low-dose oral interferon is Fundamentally Different from high dose injectable interferon. In this site, we will show the fun...

Avaxia Biologics, Inc.

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and ...

Flamel Technologies, S.A.

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel's Medusa technology is designed to deliver controlled-release formulations of therapeutic proteins and peptides and other molecules, without reduction in bioactivity. MicropumpÂ...

Supernus Pharmaceuticals, Inc

Headquartered in Rockville, MD, Supernus Pharmaceuticals, Inc. (formerly Shire Laboratories) is a specialty pharmaceuticals company that has a broad portfolio of proven and patented drug delivery technologies. Among its key technologies are ProScreen® and OptiScreen® for lead selection and formulation optimization, Microtrol®, Solutrol® and EnSoTrol®, its oral controlled release technologies,...

Jennerex Biotherapeutics

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse a...

Intec Pharma Ltd.

Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and s...

Flamel Technologies S.A.

Flamel Technologies is a drug delivery company with two intellectual property platforms: Micropump, for the controlled release of drugs best absorbed in the small intestine; and Medusa, for the controlled release of proteins, peptides, and other molecules injected subcutaneously or administered intravenously. Both of these platforms offer potential advanta...

LifeWave Ltd

Incorporated in 2000, LifeWave Ltd. is a premier provider of innovative medical device in the field of Advanced Wound Management. The Company has developed an extensively researched and clinically-validated product that represents a truly novel approach in addressing the critical medical issue of chronic wounds care. LifeWave is currently focused on introducing its product to global markets. Chron...

izun Pharmaceuticals

Izun Pharmaceuticals Ltd. is an emerging biopharmaceutical company with a product portfolio of powerful non-steroidal topical oral anti-inflammatory therapies with superior efficacy and safety to current periodontal treatments. The Company's core technology utilizes naturally derived pharmaceutical actives for the treatment of oral disease with inflammatory components. The novel therapies co...

Chiasma (Israel), LTD

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the GI wall, portal system and then to the systemic circulation. Chiasma creates its internal pipeline by selecting approved macromolecules that are currently available in injectable form...

vTv Therapeutics Inc. vTv Therapeutics Inc. vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflamma...


More From BioPortfolio on "A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks